SCHEMBL3530388

SCHEMBL3530388

CC(=O)Nc1ccc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cc(C)ccc5F)cc4)csc23)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK4 O00444 8/20 0.76
AURKA O14965 8/20 0.76
ABL1 P00519 8/20 0.76
NTRK1 P04629 8/20 0.76
CSF1R P07333 8/20 0.76
LYN P07948 8/20 0.76
MET P08581 8/20 0.76
KIT P10721 8/20 0.76
FGFR1 P11362 8/20 0.76
FLT1 P17948 8/20 0.76
BLK P51451 8/20 0.76
NEK2 P51955 8/20 0.76
STK3 Q13188 8/20 0.76
ROCK1 Q13464 8/20 0.76
NTRK2 Q16620 8/20 0.76
LCK P06239 7/20 0.76
INSR P06213 7/20 0.76
SRC P12931 7/20 0.76
RPS6KB1 P23443 7/20 0.76
EPHA2 P29317 7/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1378518 0.93 KDR (0.79) PLK4AURKAABL1NTRK1CSF1R
SCHEMBL3532643 0.92 KDR (0.75) PLK4AURKAABL1NTRK1CSF1R
SCHEMBL3534099 0.91 KDR (0.76) PLK4AURKAABL1NTRK1CSF1R
SCHEMBL3526685 0.90 KDR (0.80) PLK4AURKAABL1NTRK1CSF1R
SCHEMBL3526057 0.90 PLK4 (0.71) PLK4AURKAABL1NTRK1CSF1R
SCHEMBL3532104 0.90 PLK4 (0.71) PLK4AURKAABL1NTRK1CSF1R
SCHEMBL1379004 0.90 KDR (0.77) PLK4AURKAABL1NTRK1CSF1R
SCHEMBL3528193 0.89 PLK4 (0.70) PLK4AURKAABL1NTRK1CSF1R
SCHEMBL27640546 0.89 KDR (0.65) PLK4AURKAABL1NTRK1CSF1R
SCHEMBL3529794 0.88 FLT1 (0.70) PLK4AURKAABL1NTRK1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
EP-1648905-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS Abbott Laboratories (US) 2006-04-26 EP disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
WO-2005010009-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK PLK4 442/4885AURKA 207/4885ABL1 1/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK PLK4 442/4885AURKA 207/4885ABL1 1/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK PLK4 442/4885AURKA 207/4885ABL1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.